Search clinical trials for: benserazid

Total 28 results

Sir Run Run Shaw Hospital

Recruiting

Molecular Basis of Loss Aversion

Healthy

China
Peking University Third Hospital
Chinese Academy of Sciences

Recruiting

Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease

Parkinson Disease | Memory Impairment

China
Phoenicia BioScience
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

The BENeFiTS Trial in Beta Thalassemia Intermedia (PB04-001)

Sickle Cell Disease | Beta Thalassemia Intermedia

United States, Canada
IRCCS San Raffaele Roma
Agenzia Italiana del Farmaco

Completed

Levodopa Benserazide Generic Formulation Versus the Originator (FARM9X59Y4)

Parkinson Disease

Italy
Ankara Ataturk Sanatorium Training and Research...

Enrolling by invitation

Comparison of Dopamin Level in Idiopathic Parkinson's Patients

Parkinson Disease | Treatment Adherence

Turkey
Medical University of Warsaw
Human Biome Institute S.A.

Active, not recruiting

Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease (EFFACE-PD)

Parkinson Disease

Poland
SK Chemicals Co., Ltd.

Completed

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Parkinson Disease

Korea, Republic of
Seoul National University Hospital
Samsung Medical Center; SMG-SNU Boramae Medical Center

Completed

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON

Parkinson Disease

Korea, Republic of
Impel Pharmaceuticals

Completed

Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal (THOR201)

Parkinson's Disease

Australia
University of Zurich
Swiss Federal Institute of Technology

Completed

Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission

Healthy | Schizotypal Personality

Switzerland
Bial - Portela C S.A.

Completed

Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon

Parkinson Disease
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
ASST Gaetano Pini-CTO
Grisons Foundation for Parkinson's Disease

Completed

Mucuna Pruriens Therapy in Parkinson's Disease

Parkinson's Disease

Bolivia
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Parkinson's Disease

Romania, Ukraine
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Parkinson Disease

Canada
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
University Hospital, Geneva

Completed

Effect of Dopaminergic Medication on Recovery of Aphasia

Aphasia

Switzerland
Boehringer Ingelheim

Completed

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

Restless Legs Syndrome

Switzerland
University of Buenos Aires
Laboratorios Phoenix S.A.I.C.y F.

Completed

Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers (PHOE10903)

Healthy Volunteers

3

Subscribe